Supply Chain entity

John Moolenaar

Person

All 1 tracked stories fall under one category: regulation. John Moolenaar is most often covered alongside Active Pharmaceutical Ingredients (APIs), which appears in 1 of these 1 story. At 8, the average consequence score sits above the same-window beat average of 6.6.

Last mentioned: Aug 15, 2026

Entity pulse

Recent coverage · John Moolenaar

1 story
8 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about John Moolenaar

All 1 tracked stories fall under one category: regulation. John Moolenaar is most often covered alongside Active Pharmaceutical Ingredients (APIs), which appears in 1 of these 1 story. At 8, the average consequence score sits above the same-window beat average of 6.6. They are better corroborated than the beat average, carrying 3 original sources each against 2.6 for the same window. We currently track 1 Supply Chain story that mention John Moolenaar, all published on March 19, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 36 Supply Chain stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering John Moolenaar. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning John Moolenaar 1

Trade Policy Negative

US Lawmakers Warn of Growing Dependence on Chinese Pharmaceutical Supply Chains

US lawmakers are raising alarms over the pharmaceutical industry's reliance on Chinese ingredients, warning that Beijing is applying its 'rare earths playbook' to dominate global medicine. A House Select Committee hearing highlighted concerns that China's control over active pharmaceutical ingredients and the biotech pipeline poses a strategic threat to American healthcare security.

3 sources

John Moolenaar is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.